- Ashton B A, Ashton I K, Marshall M J. Localisation of vitronectin receptor immunoreactivity and tartrate-resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis. Ann Rheum Dis 1993; 52: 133-7.
- Athanasou N A, Quinn J, Horton M A. New sites of cellular vitronectin receptor immunoreactivity detected with osteoclast-reacting monoclonal antibodies 13C2 and 23C6. Bone Miner 1990; 8:7-22.
- Darling J M, Goldring SR, Harada Y. Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts. Am J Pathol 1997; 150: 1383-93.
- Evans A L, Kokubo T, Ishibashi O. Localization of cathepsin K in human osteoclast by in situ hybridization and immunohistochemistry. Bone 1997; 20: 81-6.
- Fujikawa Y, Athanasou N A.Pathological bone resorption in rheumatic disease. Jap J Rheum 1998; 8: 355-67.
- Fujikawa Y, Shingu M, Torisu T. Bone resorption by tartrate-resistant acid phosphatase-positive raultinuclear cells isolated from rheumatoid arthritis. Br J Rheum 1996a; 35: 213-7.
- Fujikawa Y, Sabokbar A, Neale S. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996b; 55: 816-22.
- Fujikawa Y, Quinn J, Sabokbar A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996c; 137:4058-60.
- Gravallese E M, Harada Y, Wang J T, Corn A H, Thornhill T S. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943-51.
- Hammarstrom L E, Hanker J S, Toverud S U.Cellular differences in acid phosphatase isoenzymes in bone and teeth. Clin Orthop 1971; 78: 151-67.
- Hummel K M, Petrow P K, Franz J K. Cysteine protease cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at site of synovial bone destruction. J Rheum 1998; 25: 1887-94.
- Lacey D L, Timms E, Tan H L. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
- Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K,Yasuda H. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. BBRC 1998; 246: 199-204.
- Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982; 34: 285-90.
- Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39: 115-24.
- Suda T, Takahashi N, Martin T J.Modulation of osteoclast differentiation. Endocr Rev 1992; 13: 66-80.
- Takayanagi H, Oda H, Yamamoto S. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997; 240: 279-86.
- Wilinson L S, Pitsillides A A, Edwards J C. Giant cells in arthritic synovium. Ann Rheum Dis 1993; 52: 182-4.
- Yasuda H, Shima N, Nakagawa N. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sei USA 1998; 95: 3597-602.
Acta Orthopaedica Scandinavica
Volume 71, 2000 - Issue 4